Analyst picks & changes

Genentech Inc.

(GNE)

Business: Cardiopulmonary

Oppenheimer's Geller said the failure of GNE's

Pulmozyme

in chronic obstructive pulmonary disease (COPD) wasn't surprising, because the product already had failed against bronchiectasis, a form of chronic bronchitis (see BioCentury Extra July 11). However, he said, since COPD was an important indication for

Read the full 502 word article

How to gain access

Continue reading with a
two-week free trial.